← The Wire
MYGNNasdaq
MYRIAD GENETICS INC
In Vitro & In Vivo Diagnostic Substances · DE · CIK 899923
Myriad Genetics develops and commercializes molecular tests for genetic insights to guide disease risk assessment and treatment decisions
red 8-K · 90d
$409M
Market cap
$5.85
Last close
-0.5%
1D
+30.0%
5D
1.9M
Volume
Price · last 39 sessions+18.4%
May 4L $3.55 · H $5.88Jun 29
224
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KExecutive ChangeJun 23, 20268-KExecutive Change · Shareholder VoteJun 4, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 14, 2026DEF 14ADEF 14AApr 14, 202610-K10-KFeb 24, 20268-KResults of OperationsFeb 23, 20268-KResults of OperationsJan 12, 202610-Q10-QNov 4, 20258-K/AResults of OperationsNov 4, 20258-KResults of OperationsNov 3, 20258-KExecutive ChangeOct 7, 20258-KExecutive ChangeOct 3, 20258-KExecutive ChangeAug 18, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 5, 20258-KMaterial Agreement · New Debt / ObligationJul 31, 20258-KExecutive Change · Shareholder VoteJun 5, 202510-Q10-QMay 7, 20258-KResults of OperationsMay 6, 2025DEFA14ADEFA14AApr 9, 2025DEF 14ADEF 14AApr 9, 202510-K10-KFeb 28, 20258-KExecutive Change · Results of OperationsFeb 24, 20258-KResults of OperationsJan 15, 20258-KExecutive ChangeDec 10, 20248-KReg FD DisclosureNov 26, 202410-Q10-QNov 8, 20248-KResults of OperationsNov 7, 20248-KResults of OperationsOct 9, 20248-KReg FD DisclosureSep 4, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 6, 20248-KShareholder VoteJun 6, 20248-KReg FD DisclosureJun 3, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 7, 2024SC 13GSC 13GMay 1, 2024SC 13GSC 13GApr 25, 2024DEFA14ADEFA14AApr 17, 2024DEF 14ADEF 14AApr 17, 2024SC 13GSC 13GMar 18, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 27, 20248-KResults of OperationsJan 16, 20248-KExecutive Change · Reg FD DisclosureDec 21, 20238-KMaterial AgreementNov 13, 2023424B5424B5Nov 13, 20238-KCompany UpdateNov 9, 2023424B5424B5Nov 8, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 6, 20238-KExecutive ChangeNov 1, 20238-KMaterial AgreementOct 31, 2023SC 13GSC 13GOct 17, 20238-KReg FD DisclosureOct 11, 20238-KExecutive Change · Reg FD DisclosureOct 5, 202310-Q10-QAug 4, 20238-KResults of Operations · Equity IssuanceAug 3, 20238-KMaterial Agreement · New Debt / ObligationJul 6, 20238-KExecutive Change · Bylaw AmendmentJun 2, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 3, 2023DEFA14ADEFA14AApr 12, 2023DEF 14ADEF 14AApr 12, 2023SC 13GSC 13GMar 1, 202310-K10-KMar 1, 20238-KResults of OperationsFeb 28, 202310-Q10-QNov 2, 20228-KResults of Operations · Reg FD DisclosureNov 1, 202210-Q10-QAug 5, 20228-KResults of OperationsAug 4, 20228-KMaterial Agreement · New Debt / ObligationJul 27, 20228-KExecutive ChangeJun 30, 20228-KExecutive Change · Shareholder VoteJun 2, 2022SC 13GPRIMARY DOCUMENTMay 12, 202210-Q10-QMay 6, 20228-KResults of OperationsMay 5, 2022DEFA14ADEFA14AApr 14, 2022
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Mar 9, 2026: 2 insiders bought $695K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 2026 | Raha Samraat S.President and CEO | Buy | 40,000 | $5.00 | $200K |
| Feb 27, 2026 | Phanstiel S. LouiseDirector | Buy | 48,000 | $4.66 | $224K |
| Feb 26, 2026 | Phanstiel S. LouiseDirector | Buy | 50,407 | $4.80 | $242K |
| Feb 25, 2026 | Phanstiel S. LouiseDirector | Buy | 6,100 | $4.74 | $29K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance